Streetbeat News

CDIO

Cardio Diagnostics Holdings, Inc.

https://cardiodiagnosticsinc.com

Industry

Biotechnology

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Open

0.24

Mkt cap

11M

Volume

315K

High

0.26

P/E Ratio

-0.87

52-wk high

3.56

Low

0.24

Div yield

N/A

52-wk low

0.19

The article highlights significant intraday movements in healthcare stocks, with GlycoMimetics, Lixte Biotechnology, and GeneDx Holdings among the top gainers, while TransMedics Group and Coya Therapeutics are notable losers. The movements are influenced by recent earnings reports and market reactions.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 4:31 pm

Several healthcare stocks experienced significant price movements in Tuesday's pre-market session. Notable gainers include GlycoMimetics, Shuttle Pharmaceuticals, and Lixte Biotechnology, while TransMedics Group and Cardio Diagnostics Holdings were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 12:08 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant price movements. GlycoMimetics, Shuttle Pharmaceuticals, Lixte Biotechnology, NovaBay Pharmaceuticals, Immuron, and Protagenic Therapeutics saw notable gains. Conversely, TransMedics Group, Cardio Diagnostics Holdings, Biora Therapeutics, Trinity Biotech, American Well, and Healthcare Triangle experienced declines.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 12:08 pm

VF Corp shares surged 21.4% in pre-market trading after reporting better-than-expected Q2 results, with revenue of $2.8 billion and earnings of 60 cents per share. Other stocks like Shuttle Pharmaceuticals and Lixte Biotechnology also saw significant pre-market gains.

Portfolio Pulse from Avi Kapoor

October 29, 2024 | 10:12 am

In Monday's after-market session, Shuttle Pharmaceuticals, Impact BioMedical, and Onconetix saw significant stock price increases, while TransMedics Group and Cardio Diagnostics Holdings experienced notable declines. The movements were influenced by various factors, including earnings reports.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 8:31 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Eterna Therapeutics, ModivCare, Cardio Diagnostics, Autolus Therapeutics, Beyond Air, and Meihua Intl Medical Techs saw notable gains. Conversely, Humana, Carmell, Tivic Health Systems, Kairos Pharma, IGM Biosciences, and Silexion Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:05 pm

Cardio Diagnostics has received preliminary Medicare pricing from CMS for its AI-powered cardiovascular tests, PrecisionCHD and Epi+Gen CHD. This is a significant step towards securing Medicare reimbursement.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 12:32 pm

In Friday's pre-market session, several healthcare stocks experienced significant price movements. Onconetix (ONCO) led the gainers with a 77% increase, while Theriva Biologics (TOVX) led the losers with an 18.6% decrease. Other notable gainers include Establishment Labs (ESTA) and Cardio Diagnostics (CDIO), while enVVeno Medical (NVNO) and Aytu BioPharma (AYTU) were among the significant decliners.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 12:09 pm

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares surged 28.3% in pre-market trading after receiving FDA approval for Motiva Implants. Other notable pre-market movers include Fangdd Network Group Ltd. (NASDAQ:DUO), Onconetix, Inc. (NASDAQ:ONCO), and Bristol-Myers Squibb Company (NYSE:BMY), which saw significant gains due to various positive developments.

Portfolio Pulse from Avi Kapoor

September 27, 2024 | 10:46 am

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included Cardio Diagnostics Holdings, TC BioPharm, and Seres Therapeutics, while Cue Biopharma and enVVeno Medical were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.